Table 1.
Characteristics of studies included in the meta-analysis
| Study | Year | Country | Sample size | Cancer types | Phenotype | Cut-off | Age | Follow-up (month) | NOS scores | Survival analysis |
|---|---|---|---|---|---|---|---|---|---|---|
| Zhang, Y | 2017 | China | 76 | rectal carcinoma | HLA-DR−CD33+CD11b+ | 3.68 | NA | NA | 5 | OS |
| Yang, G | 2017 | China | 113 | bladder cancer | HLA-DR−CD33lowCD11b+CD3− | 21 | 66.5 (45–84) | 43 (4–60) | 6 | OS |
| Gao, X.H | 2017 | China | 183 | HCC | HLA-DR-/lowCD14− | 2.31 | NA | 24 (1.3–28.8) | 6 | OS, RFS |
| Wang, D1 | 2016 | China | 92 | HCC | HLA-DR-/lowCD14− | 14.6 | NA | NA | 6 | OS |
| Wang, D2 | 2016 | China | 92 | HCC | HLA-DR-/lowCD14− | 14.6 | NA | NA | 6 | OS |
| Choi, H.S | 2016 | Korea | 28 | GC | HLA-DR−CD11b+CD14+CD45+ | 2.2 | 37–88 | 29 (10–42) | 8 | OS, DFS |
| Zhang, H1 | 2015 | China | 32 | NK/T lymphoma | HLA-DR−CD33+CD11b+ | 1.1 | 40.5 (17–70) | 52 | 7 | OS, DFS |
| Zhang, H2 | 2015 | China | 32 | NK/T lymphoma | HLA-DR−CD33+CD11b+CD14+ | 0.7 | NA | NA | 7 | OS, DFS |
| Yuan, L1 | 2015 | China | 64 | rectal carcinoma | Lin−HLA-DR−CD33+CD11b+ | 3.78 | 62 (38–76) | 72 | 5 | OS |
| Yuan, L2 | 2015 | China | 64 | rectal carcinoma | Lin−HLA-DR−CD33+CD11b+ | 2.11 | NA | NA | 5 | OS |
| Tian, T | 2015 | China | 42 | small-cell lung cancer | HLA-DR-/lowCD14− | 21.7 | 62.4 | 36 | 6 | OS |
| Jiang, H | 2015 | Germany | 51 | advanced melanoma | HLA-DR−CD11b+CD14+CD15− | 2.3 | 61.26 (33–88) | 7 | 8 | OS |
| Huang, H | 2015 | China | 78 | ESCC | HLA-DR-/lowCD14− | 2.38 | 62.4 (46–77) | 42 | 7 | OS |
| Chevolet, I | 2015 | Belgium | 69 | melanoma | Lin−HLA-DR−CD33+CD11b+ | 4.13 | NA | 39 | 7 | OS |
| Weide, B | 2014 | Australia | 94 | advanced melanoma | HLA-DR-/lowCD11b+CD14+ | 11 | NA | 15 | 9 | OS |
| Wang, L | 2013 | Singapore | 40 | GC | Lin−HLA-DR−CD33+ | 4 | NA | NA | 7 | OS |
| Arihara, F1 | 2013 | Japan | 123 | HCC | HLA-DR-/lowCD14− | 22 | NA | NA | 7 | RFS-U |
| Arihara, F2 | 2013 | Japan | 123 | HCC | HLA-DR-/lowCD14− | 22 | NA | NA | 7 | RFS-U, RFS-M |
| Solito, S1 | 2011 | Italy | 25 | colorectal cancer | Lin−HLA-DR−CD33+CD11b+ | 2.54 | NA | NA | 9 | OS |
| Solito, S2 | 2011 | Italy | 26 | bresat cancer | Lin−HLA-DR−CD33+CD11b+ | 3.17 | NA | NA | 9 | OS |
| Gabitass, R.F | 2011 | UK | 256 | pancreatic, esophageal and gastric cancer | Linlow/-HLA-DR−CD33+CD11b+ | 2 | NA | NA | 7 | OS |
HCC hepatocelluar carcinoma, GC gastric cancer, ESCC esophageal squamous cell carcinoma
NA not applicable, NOS the Newcastle–Ottawa Quality Assessment Scale
OS overall survival, DFS disease-free survival, RFS recurrence-free survival, U&M univariate & multivariate survival analysis